BaiotaAmu monoanti-singdo China has been approved to treat non-infectious vitinomyitis new indications.

Guide: As of today, a total of 3 kinds of Adamu monoto-anti-drug approved in China.
, Aotai Biopharmaceutical Co., Ltd. recently received the approval of the State Drug Administration issued on the Adamu sing-in-injection (commodity name: ®) of the "Notice no. 2020B04337), the new drug was approved for new indications: vine membraneitis.
The Adamu monotomotic biosimilar drug developed for Theoty ®, is a recombinant monoclonal antibody developed by CHO cell expression.
The ® blocked the inflameding effect of TNF-alpha by binding to TNF-alpha-specificity and neutralized and biologically functional.
the acquisition of the "Notice of Approval of Supplementary Drug Applications" is a further complement to The ® Indications of Grei.
as of the date of disclosure of this announcement, a total of 3 domestic approved Adamu monoto-drug drugs, listed and other potential competitors may have a pioneer advantage, The ® may face fierce market competition in the future.
.